Your browser doesn't support javascript.
loading
BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma.
Herbert, Katharine; Binet, Romuald; Lambert, Jean-Philippe; Louphrasitthiphol, Pakavarin; Kalkavan, Halime; Sesma-Sanz, Laura; Robles-Espinoza, Carla Daniela; Sarkar, Sovan; Suer, Eda; Andrews, Sarah; Chauhan, Jagat; Roberts, Nicola D; Middleton, Mark R; Gingras, Anne-Claude; Masson, Jean-Yves; Larue, Lionel; Falletta, Paola; Goding, Colin R.
Afiliação
  • Herbert K; Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom.
  • Binet R; Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom.
  • Lambert JP; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada.
  • Louphrasitthiphol P; Department of Molecular Medicine, Cancer Research Centre, Université Laval, Quebec G1V 0A6, Canada; CHU de Québec Research Center, CHUL, Quebec G1V 4G2, Canada.
  • Kalkavan H; Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom.
  • Sesma-Sanz L; Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
  • Robles-Espinoza CD; Genome Stability Laboratory, CHU de Oncology Division, Québec Research Center, Québec City, Quebec G1R 3S3, Canada.
  • Sarkar S; Department of Molecular Biology, Medical Biochemistry, and Pathology, Laval University Cancer Research Center, Québec City, Quebec G1V 0A6, Canada.
  • Suer E; Laboratorio Internacional de Investigación Sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro 76230, Mexico.
  • Andrews S; Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, United Kingdom.
  • Chauhan J; Department of Oncology, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom.
  • Roberts ND; Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom.
  • Middleton MR; Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom.
  • Gingras AC; Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom.
  • Masson JY; The Cancer Genome Project, The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, United Kingdom.
  • Larue L; Department of Oncology, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom.
  • Falletta P; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada.
  • Goding CR; Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
Genes Dev ; 33(5-6): 310-332, 2019 03 01.
Article em En | MEDLINE | ID: mdl-30804224
ABSTRACT
Whether cell types exposed to a high level of environmental insults possess cell type-specific prosurvival mechanisms or enhanced DNA damage repair capacity is not well understood. BRN2 is a tissue-restricted POU domain transcription factor implicated in neural development and several cancers. In melanoma, BRN2 plays a key role in promoting invasion and regulating proliferation. Here we found, surprisingly, that rather than interacting with transcription cofactors, BRN2 is instead associated with DNA damage response proteins and directly binds PARP1 and Ku70/Ku80. Rapid PARP1-dependent BRN2 association with sites of DNA damage facilitates recruitment of Ku80 and reprograms DNA damage repair by promoting Ku-dependent nonhomologous end-joining (NHEJ) at the expense of homologous recombination. BRN2 also suppresses an apoptosis-associated gene expression program to protect against UVB-, chemotherapy- and vemurafenib-induced apoptosis. Remarkably, BRN2 expression also correlates with a high single-nucleotide variation prevalence in human melanomas. By promoting error-prone DNA damage repair via NHEJ and suppressing apoptosis of damaged cells, our results suggest that BRN2 contributes to the generation of melanomas with a high mutation burden. Our findings highlight a novel role for a key transcription factor in reprogramming DNA damage repair and suggest that BRN2 may impact the response to DNA-damaging agents in BRN2-expressing cancers.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Apoptose / Proteínas de Homeodomínio / Fatores do Domínio POU / Reparo do DNA por Junção de Extremidades / Melanoma / Mutação Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Apoptose / Proteínas de Homeodomínio / Fatores do Domínio POU / Reparo do DNA por Junção de Extremidades / Melanoma / Mutação Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article